0
Obstructive Lung Diseases |

Factors Associated With Acute Exacerbation in COPD Patients With Mild-to-Moderate Airflow Limitation

Yong Il Hwang, MD; Chang Youl Lee, MD; Sunghoon Park, MD; Joo Hee Kim, MD; Yong Bum Park, MD; Seung Hun Jang, MD; Kwang Ha Yoo, MD; Chin Kook Rhee, MD; Hyoung Kyu Yoon, MD; Ki-Suck Jung, MD
Author and Funding Information

Hallym University Sacred Heart Hospital, Anyang-si, Korea (the Republic of)


Chest. 2015;148(4_MeetingAbstracts):701A. doi:10.1378/chest.2279614
Text Size: A A A
Published online

Abstract

SESSION TITLE: COPD Posters III

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 28, 2015 at 01:30 PM - 02:30 PM

PURPOSE: The aim of this study was to compare the clinical characteristics of patients with mild-to-moderate airflow limitation according to the experience the acute exacerbation.

METHODS: The patients included in the present study were from the Kore­an COPD Subtype Study (KOCOSS) cohort. The patients were recruited from 37 referral hospitals in Korea. The definition of COPD was adopted by the GOLD guideline. We obtained the clinical data from the medical record and compared the clinical, spirometric data according to the development of exacerbation during the follow-up period

RESULTS: A total of 570 patients with mild-to-moderate airflow limitation were enrolled. A total of 9.3% had FEV1>80% of predicted value. The mean CAT score was 13.9 ± 6.9. The mean SGRQ-c was 30.4 ± 6.5. There were 114 patients (20%) who had experienced one year before enrollment. A total of 17.4% and 14.2% of patients had history of measles and pneumonia, respectively. When adopting 2011 GOLD classification, 24.9% and 74.7% of the patients were classified as GOLD A and B, respectively. During the first 2 years of follow-up period, 17.5% of patients experienced acute exacerbation. SGRQ-c and CAT score were significantly higher in patients with exacerbation than patients without exacerbation (36.3 ± 2.0 vs. 25.6±1.5, 16.6±79 vs. 12.1±6.0, respectively). Patient with exacerbation had allergic rhinitis, hyperlipidemia more frequently, which is statistically significant. A total of 83.3% of patients with history of exacerbation at enrollment experienced exacerbation during the follow-up period. A total 22.0% and 24.1% of the patients with exacerbation had history of pneumonia and measles, which is higher than that of patients without exacerbation (p=0.014 and 0.044, respectively).

CONCLUSIONS: A total of 17.5% of mild to moderate COPD patients experienced acute exacerbation during 2 years of follow up. Development of acute exacerbations is associated with poor quality of life, hyperlipidemia, allergic rhinitis, history of acute exacerbation, history of pneumonia and history of measles

CLINICAL IMPLICATIONS: A subsequent number of patients with mild-to-moderate airflow limitation experienced exacerbations. Presence of co-morbidities, quality of life and past medical history should be assessed meticulously in order to differentiate patients with high risk of exacerbation.

DISCLOSURE: The following authors have nothing to disclose: Yong Il Hwang, Chang Youl Lee, Sunghoon Park, Joo Hee Kim, Yong Bum Park, Seung Hun Jang, Kwang Ha Yoo, Chin Kook Rhee, Hyoung Kyu Yoon, Ki-Suck Jung

No Product/Research Disclosure Information


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543